<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229123</url>
  </required_header>
  <id_info>
    <org_study_id>2014-000791-26</org_study_id>
    <nct_id>NCT02229123</nct_id>
  </id_info>
  <brief_title>Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study</brief_title>
  <acronym>LEVNEONAT1</acronym>
  <official_title>Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Georges Pompidou Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      LEVNEONAT is a multicentre French clinical trials with the aim to develop new treatment
      strategies for the treatment of neonatal seizures using Levetiracetam. The purpose of this
      study is to determine the correct dosing, safety and efficacy for intravenous levetiracetam
      as first line treatment in term new born babies with seizures. This new anticonvulsivant
      drug is a promising treatment for seizures in newborns.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Optimal dose finding</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The optimal dose is defined as achieving effective seizure reduction: reduction of electrographic seizure (measured by EEG) burden by &gt; 80% during the 3rd and 4th hour after the first levetiracetam administration compared to a 2 hour epoch prior to levetiracetam administration. No need to recue AED within 48 hours.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Neonatal Seizures</condition>
  <arm_group>
    <arm_group_label>Intravenous levetiracetam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Levetiracetam</intervention_name>
    <description>Intravenous Levetiracetam 40 to 60 mg/kg loading dose. 7.5 to 15 mg/kg 8 hourly maintenance as determined by the dose escalation design</description>
    <arm_group_label>Intravenous levetiracetam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female term baby with gestational of 37-43 weeks and postnatal age &lt; or= 72
             hours one or more of the following :

          -  APGAR score &lt; 5 at 5 mins

          -  Umbilical cord or arterial blood sample (within one hour after birth): pH &lt;7.0 or
             base deficit &gt; 16 mmol/L

          -  Postnatal resuscitation still required 10 minutes after birth

          -  Clinically evolving encephalopathy

          -  EEG: equal to or more than 3 min cumulative seizures, or 2 or more seizures of&gt;30 sec
             duration over 2 hours period within 72 hours of life

          -  Written informed consent of parent or guardian

          -  EEG monitoring has commenced within the first 72 hours of birth

        Exclusion Criteria:

          -  -Suspected or confirmed brain malformation, inborn error of metabolism, genetic
             syndrome or major congenital malformation

          -  Congenital (in utero) infection (TORCH)

          -  Babies who have received phenobarbitone or any other anticonvulsive medication than a
             bolus of midazolam for intubation within the last 24 hours

          -  Anuria/renal failure defined as serum creatinine &gt; 150 micromol/L
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>37 Weeks</minimum_age>
    <maximum_age>43 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ELIE SALIBA, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Tours</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geraldine FAVRAIS, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elie Saliba, Pr</last_name>
    <phone>0247478093</phone>
    <email>elie.saliba@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Kipper</last_name>
    <phone>0247474665</phone>
    <email>alexandra.kipper@univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de réanimation néonatale</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent Storme, Pr</last_name>
      <email>laurent.storme@chru-lille.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elie Saliba, Pr</last_name>
      <phone>0247478093</phone>
      <email>elie.saliba@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Storme, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de réanimation néonatale</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-christophe Roze, Pr</last_name>
      <email>jeanchristophe.roze@chu-nantes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saliba</last_name>
      <phone>0247478093</phone>
      <email>elie.saliba@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Jean-christophe Roze, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de néonatologie et réanimation néonatale</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Khaled Husseini</last_name>
      <email>khaled.husseini@chu-poitiers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elie Saliba, Pr</last_name>
      <phone>0247478093</phone>
      <email>elie.saliba@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Khaled Husseini, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Néonatologie</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick Pladys, Pr</last_name>
      <email>patrick.pladys@chu-rennes.fr</email>
    </contact>
    <contact_backup>
      <last_name>ELIE SALIBA, Pr</last_name>
      <phone>0247478093</phone>
      <email>elie.saliba@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick Pladys, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie néonatale et réanimation</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra Chadie, Dr</last_name>
      <email>alexandra.chadie@chu-rouen.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elie Saliba</last_name>
      <phone>0247478093</phone>
      <email>elie.saliba@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Alexandra Chadie, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation pédiatrique, Néonatologie</name>
      <address>
        <city>Tours</city>
        <zip>37 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elie Saliba, Pr</last_name>
      <email>elie.saliba@univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandra Kipper</last_name>
      <phone>0247474665</phone>
      <email>alexandra.kipper@univ-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Elie Saliba, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <lastchanged_date>September 18, 2014</lastchanged_date>
  <firstreceived_date>August 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seizures</keyword>
  <keyword>neonates</keyword>
  <keyword>anticonvulsants treatment</keyword>
  <keyword>levetiracetam</keyword>
  <keyword>hypoxic-ischemic encephalopathy</keyword>
  <keyword>electroencephalography</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
